Century Therapeutics (IPSC) Invested Capital (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Invested Capital data on file, last reported at $266.7 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $266.7 million, up 10.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $266.7 million (up 10.92% YoY), and the FY2025 annual result was $162.7 million, up 0.82% from the prior year.
• Invested Capital improved to $266.7 million in Q1 2026 per IPSC's latest filing, from $162.7 million in the prior quarter.
• Over five years, Invested Capital peaked at $386.7 million in Q1 2022 and troughed at $161.4 million in Q4 2024.
• A 5-year average of $244.1 million and a median of $222.1 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2023: Invested Capital soared 522.32% in 2022, then slumped 40.26% in 2023.
• A 5-year view of Invested Capital shows it stood at $309.2 million in 2022, then tumbled by 40.26% to $184.8 million in 2023, then dropped by 12.66% to $161.4 million in 2024, then increased by 0.82% to $162.7 million in 2025, then jumped by 63.92% to $266.7 million in 2026.
• Business Quant data shows IPSC's Invested Capital at $266.7 million in Q1 2026, $162.7 million in Q4 2025, and $184.7 million in Q3 2025.